News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Alnylam Pharmaceuticals Inc. (ALNY) stock has fallen to a 52-week low of $226.04, reflecting a 26.93% decrease over the past year. Despite recent challenges, including a revenue miss in Q2, the stock shows potential for stabilization with a 6.65% gain over the last week …
Sharemaestro market context Price below Trend Line 52 weeks -52.7% · Next-week setup negative 40.4%Alnylam Pharmaceuticals (ALNY) reported Q2 2026 revenue of $1.29 billion, a 66.9% year-over-year increase, and an EPS of $1.84. While revenue missed the Zacks Consensus Estimate by -2.09% and EPS by -10.24%, the article highlights various key product revenue metrics, showing both gains and …
Alnylam Pharmaceuticals, Inc. published its Q2 2026 earnings call presentation on July 30, 2026. The company reported an EPS of $1.84, missing estimates by $0.30, and revenue of $1.29 billion, a 66.86% year-over-year increase, but still missing by $29.34 million. The presentation provides detailed …
Alnylam Pharmaceuticals (ALNY) reported Q2 earnings of $1.84 per share, missing the Zacks Consensus Estimate of $2.05, and revenues of $1.29 billion, also falling short of expectations. Despite beating EPS estimates in three of the last four quarters, the company's stock has declined nearly …
Alnylam Pharmaceuticals (NASDAQ:ALNY) experienced a significant drop in share price after reporting a substantial revenue miss for Q2 2026 and lowering its full-year guidance, despite beating EPS estimates. The lowered outlook for its flagship TTR product, particularly AMVUTTRA, signals slower-than-expected growth, worrying investors about …
Alnylam Pharmaceuticals announced its expectation for 2026 total net product revenue to be between $4.70 billion and $5.10 billion. This news comes alongside other recent company updates, including Q2 2026 earnings results and adjustments to its revenue guidance. The company, specializing in RNA interference …
Alnylam Pharmaceuticals reported its Q2 adjusted EPS at USD 1.84, surpassing the IBES estimate of USD 1.55. This brief update highlights the company's better-than-expected financial performance for the quarter.
The article provides a Q2 earnings snapshot for Alnylam. However, the full content of the article is missing, making it impossible to summarize specific financial details or performance indicators.
Alnylam Pharmaceuticals' stock is considered 34% undervalued, with a fair value of $434.72 compared to its last close of $286.95, following recent Alzheimer's pipeline updates. Despite a mixed stock performance this year, the company's RNAi therapies and increasing R&D efficiency suggest significant future growth …
Alnylam Pharmaceuticals (ALNY) reported a 6.3% stock increase after presenting new Alzheimer's disease RNAi data, including long-term safety and biomarker reductions for mivelsiran and ALN-5288, at the Alzheimer's Association International Conference. The company also announced its first quarter exceeding $1 billion in product revenue, …
Alnylam Pharmaceuticals Inc. is set to report second-quarter earnings, with investors focused on Amvuttra sales to address concerns about the ATTR-CM market. Despite a bullish Wall Street outlook and significant revenue growth, the stock has fallen from its highs due to uncertainty surrounding long-term …
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is set to report its Q2 earnings, with its stock currently appearing 45.6% undervalued according to GuruFocus' GF Value™ metric. The company, a pioneer in RNAi therapeutics, holds a strong GF Score™ of 76/100, driven by robust growth and …
Alnylam Pharmaceuticals (ALNY) is projected by Wall Street analysts to report significant Q2 growth, with earnings expected to rise by 540.6% to $2.05 per share and revenues by 70.4% to $1.32 billion. Key product revenue estimates show varying growth rates, with Amvuttra leading with …
This article provides a comprehensive stock analysis of Alnylam Pharmaceuticals Inc (ALNY), highlighting its strong fundamentals, high growth potential, and "fairly valued" status. It notes that institutional ownership is high and analysts largely rate it as a "Buy" with a target price of $440.59. …
Alnylam Pharmaceuticals recently announced progress in its Alzheimer's disease pipeline, including advancing mivelsiran into Phase 2 trials and a new first-in-human trial for ALN-5288. While this diversification is positive for the long term, the article states that the primary near-term focus and risk for …
Alnylam Pharmaceuticals (NASDAQ: ALNY) had approximately 2,566 employees worldwide as of March 2026, a 0.8% decline year-over-year but a 21.6% growth since 2023. The company is actively hiring, with 261 job postings in 2026, and its workforce is primarily concentrated in the United States. …
Alnylam Pharmaceuticals Inc (ALNY) currently holds an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional shareholding stands at 100.11%, a slight decrease quarter-over-quarter. ETHSX is the largest institutional shareholder, with a significant increase in its holdings.
This article provides a detailed breakdown of Alnylam Pharmaceuticals Inc (ALNY) shareholder structure, listing major shareholders, their proportion of holdings, and how these figures have changed. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) and presents institutional shareholding trends over several …
Alnylam Pharmaceuticals (ALNY) is potentially 38% undervalued according to Simply Wall St, despite a recent 17.35% decline in its 1-year total shareholder return. The company is receiving attention for its RNAi approach to Alzheimer's and cerebral amyloid angiopathy, with a "fair value" estimate of …
This article provides the coupon profile for the ALNY5653584 bond issued by Alnylam Pharmaceuticals, Inc. The bond has a coupon rate of 1.00% and the next interest payment is scheduled for September 15, 2026. It highlights the interest payment overview and offers more detailed …
This page provides current stock information for Alnylam Pharmaceuticals Inc (ALNY), including its stock price, market capitalization, volume, and EPS. It also lists recent news articles related to Alnylam's earnings expectations, webcast details for financial results, and progress in neuroscience programs. The page highlights …
Alnylam Pharmaceuticals (ALNY) is expected to report a significant year-over-year increase in earnings and revenue for the quarter ended June 2026. While the consensus EPS estimate shows a positive revision, the company's Earnings ESP is negative, making it difficult to confidently predict an earnings …
This article provides a bond risk profile for Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028 (US2043QAC1) on the Frankfurt Stock Exchange. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability and make informed decisions. …
JP Morgan has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $420.00 to $400.00 per share. The firm has maintained an "Overweight" rating on the company's stock. This adjustment suggests a continued positive outlook for ALNY despite the reduced price target.
Alnylam Pharmaceuticals (ALNY) has achieved rapid adoption of AMVUTTRA in ATTR cardiomyopathy, doubling TTR franchise revenues in 2025 and projecting significant growth for 2026. The company is targeting leadership in the TTR market by 2030, aiming for a 25% revenue CAGR. AMVUTTRA demonstrates strong …
This article provides key metrics for the Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028 US2043QAC1 bond, traded on the Frankfurt Stock Exchange.
Alnylam Pharmaceuticals (ALNY) reported strong Q2 2024 results, with net product revenues up 34% year-over-year to $410.1M and total revenues reaching $660M, a 107% increase. The company raised its 2024 net product revenue guidance to $1,575M–$1,650M following positive Phase 3 study results for vutrisiran …
This article examines Alnylam Pharmaceuticals (ALNY), Insulet (PODD), and Neurocrine Biosciences (NBIX), three U.S. large-cap health care stocks. It discusses their market positioning, financial outlook, and the balance of opportunities and risks they face amidst current market conditions and upcoming earnings. The analysis highlights …
Alnylam Pharmaceuticals presented promising Phase 1 and 2 updates on its RNAi candidate mivelsiran for early-onset and Down syndrome-associated Alzheimer’s disease, and other neuroscience programs, at AAIC 2026. The company reported long-term biomarker reductions and a favorable safety profile for mivelsiran, and completed enrollment …
Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a 28.79% year-to-date and nearly 13% annual decline amidst biotechnology sector challenges. Despite the downturn, analysts maintain a bullish outlook with price targets up to $550, citing significant upside potential. Recent …
Alnylam Pharmaceuticals (ALNY) recently initiated a Phase 2 trial for mivelsiran in Down syndrome-associated Alzheimer’s, yet its stock price has declined by over 10% in the past week. Despite recent drops, the company is considered undervalued by analysts, trading at $267.47 against a narrative …
Sharemaestro market context Price below Trend Line 52 weeks -52.7% · Next-week setup negative 40.4%Alnylam Pharmaceuticals is holding its annual virtual meeting on May 20, 2026, where shareholders will vote on the election of three Class I directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The company reached significant milestones in …
Search by ticker symbol or company name and select a result to open its chart.